Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (DE:2TZ)
STUTTGART:2TZ
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (2TZ) Stock Price & Analysis
0 Followers
2TZ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.52 - €2.13
Previous Close€2.12
Volume0.00
Average Volume (3M)600.00
Market Cap
€3.94B
Enterprise Value€3.61B
Total Cash (Recent Filing)¥2.88B
Total Debt (Recent Filing)¥257.91M
Price to Earnings (P/E)N/A
Beta0.01
Next Earnings
Aug 09, 2024EPS EstimateN/A
Last Dividend Ex-Date
May 26, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume600
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S News
PremiumCompany Announcements
Tianjin Pharma Reports on Placement Proceeds
PremiumCompany Announcements
Tianjin Pharma Updates Continuous Risk Assessment2TZ FAQ
What was Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price range in the past 12 months?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S lowest stock price was €1.52 and its highest was €2.13 in the past 12 months.
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap?
Currently, no data Available
When is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date is Aug 09, 2024 which is in 80 days.
How were Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s earnings last quarter?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S released its earnings results on Apr 29, 2024. The company reported €0.064 earnings per share for the quarter, beating the consensus estimate of N/A by €0.064.
Is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S overvalued?
According to Wall Street analysts Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price is currently Overvalued.
Does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pay dividends?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pays a Semiannually dividend of €0.15 which represents an annual dividend yield of N/A. See more information on Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S dividends here
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S have?
Currently, no data Available
What happened to Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price movement after its last earnings report?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S reported an EPS of €0.064 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.099%.
Which hedge fund is a major shareholder of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S?
Currently, no hedge funds are holding shares in DE:2TZ
---
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Zhong Xin Pharmaceutical Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
---
Technical Analysis
---